The study focuses on patients with stage III non-small cell lung cancer, a type of lung cancer that has grown locally but has not spread to distant parts of the body. Standard treatment for this condition often includes chemoradiotherapy, which combines chemotherapy (medicine that kills cancer cells) and radiation therapy (high‑energy rays that damage cancer cells). After completing this initial therapy, participants receive a personalized form of consolidation immunotherapy. The medication used is IMFINZI, whose active ingredient is durvalumab, given by intravenous infusion (a drip placed into a vein). Before starting the immunotherapy, a blood test looks for MRD, short for minimal residual disease, meaning any tiny amount of cancer that might still be present.

The purpose of the study is to see whether this personalized approach can keep the cancer from coming back and improve overall health. After the MRD test, the infusion is given at regular intervals for several months, and participants return for routine visits where doctors check for side effects, ask about daily well‑being, and collect information on overall health status. The study follows participants for about a year to monitor how well the cancer stays under control and how the treatment affects quality of life.